{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:46:00Z","timestamp":1792802760487,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","award":["RGPVPP-331"],"award-info":[{"award-number":["RGPVPP-331"]}],"id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jpba.2021.114276","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T18:50:45Z","timestamp":1626979845000},"page":"114276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Development and validation of UPLC\u2013MS\/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction"],"prefix":"10.1016","volume":"204","author":[{"given":"Hadir M.","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah","family":"Almomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah Z.","family":"Alzoman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen M.","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwaq A.","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114276_bib0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1155\/2012\/976203","article-title":"Properties and therapeutic application of bromelain: a review","volume":"2012","author":"Pavan","year":"2012","journal-title":"Biotechnol. Res. Int."},{"key":"10.1016\/j.jpba.2021.114276_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2009.08.001","article-title":"Bromelain\u2019s activity and potential as an anti-cancer agent: current evidence and perspectives","volume":"290","author":"Chobotova","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jpba.2021.114276_bib0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3892\/br.2016.720","article-title":"Potential role of bromelain in clinical and therapeutic applications (Review)","volume":"5","author":"Rathnavelu","year":"2016","journal-title":"Biomed. Rep."},{"issue":"11","key":"10.1016\/j.jpba.2021.114276_bib0020","first-page":"488","article-title":"A review on potential properties and therapeutic applications of bromelain","volume":"8","author":"Kwatra","year":"2019","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jpba.2021.114276_bib0025","unstructured":"J. Meschino, Bromelain, Natural Health Products Compendium Clinical Application and Mechanism of Action, Drug-Nutrient Interactions. 33\u201335, https:\/\/adeevainfo.com\/documents\/ebook\/Comphensive_Guide_to_Herbs.pdf (Accessed January 2020)."},{"issue":"10","key":"10.1016\/j.jpba.2021.114276_bib0030","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.4314\/tjpr.v14i10.27","article-title":"Effect of fruit\/vegetable-drug interactions on CYP450, OATP and p-glycoprotein: a systematic review","volume":"14","author":"Mallhi","year":"2015","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.jpba.2021.114276_bib0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11694-016-9403-3","article-title":"Effect of bromelain and papain enzymes addition on physicochemical and textural properties of squid (Loligo vulgaris)","volume":"11","author":"Gokoglu","year":"2017","journal-title":"Food Meas."},{"key":"10.1016\/j.jpba.2021.114276_bib0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.addr.2017.10.009","article-title":"The role of mucus on drug transport and its potential to affect therapeutic outcomes","volume":"124","author":"Murgia","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpba.2021.114276_bib0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2006.06.042","article-title":"Improvement of the intestinal membrane permeability of low molecular weight heparin by complexation with stem bromelain","volume":"326","author":"Grabovac","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2021.114276_bib0050","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2146\/ajhp140836","article-title":"Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer","volume":"72","author":"Croegaert","year":"2015","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jpba.2021.114276_bib0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ejca.2012.02.001","article-title":"ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development","volume":"48","author":"Scagliotti","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jpba.2021.114276_bib0060","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","article-title":"The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers","volume":"70","author":"Sasaki","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2021.114276_bib0065","first-page":"145","article-title":"Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib","volume":"8","author":"El-Osta","year":"2015","journal-title":"Pharmgenomics Pers. Med."},{"key":"10.1016\/j.jpba.2021.114276_bib0070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study","volume":"34","author":"Ou","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2021.114276_bib0075","first-page":"1","article-title":"Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects","author":"Morcos","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2021.114276_bib0080","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1124\/dmd.115.064618","article-title":"Prediction of drug-drug interactions with crizotinib as the CYP3A substrate using a physiologically based pharmacokinetic models","volume":"43","author":"Yamazaki","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.jpba.2021.114276_bib0085","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/cpdd.298","article-title":"Clinical drug\u2013drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jpba.2021.114276_bib0090","series-title":"Zykadia prescribing information","author":"US Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.jpba.2021.114276_bib0095","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00280-017-3308-7","article-title":"Assessment of drug\u2013drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK\u2011positive non\u2011small cell lung cancer","volume":"79","author":"Lau","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jpba.2021.114276_bib0100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpdd.296","article-title":"Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jpba.2021.114276_bib0105","unstructured":"Internet communication, https:\/\/www.healthline.com\/health\/digestive-health\/pineapples-acid-reflux (Accessed January 2020)."},{"key":"10.1016\/j.jpba.2021.114276_bib0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchromb.2012.08.021","article-title":"Liquid chromatography\u2013tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma","volume":"905","author":"Sparidans","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2021.114276_bib0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jchromb.2014.04.035","article-title":"Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization\u2013tandem mass spectrometry (LC-ESI\u2013MS\/MS)","volume":"960","author":"Roberts","year":"2014","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/j.jpba.2021.114276_bib0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jpha.2017.07.007","article-title":"A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor","volume":"8","author":"Bao","year":"2018","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2021.114276_bib0125","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1007\/s00216-014-8125-9","article-title":"Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies","volume":"406","author":"Heudi","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2021.114276_bib0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jpba.2016.10.010","article-title":"An UPLC\u2013MS\/MS method for the quantitation of alectinib in rat plasma","volume":"132","author":"Huang","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"5","key":"10.1016\/j.jpba.2021.114276_bib0135","first-page":"51506","article-title":"HPLC-MS\/MS method development and validation for determing stability of alectinib in human plasma samples","volume":"9","author":"Srikanth","year":"2017","journal-title":"Int. J. Current Res."},{"key":"10.1016\/j.jpba.2021.114276_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122752","article-title":"Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS\/MS in human plasma: application to therapeutic drug monitoring in patients with non-small cell lung cancer","volume":"1175","author":"Zhou","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2021.114276_bib0145","series-title":"Center for Drug Evaluation and Research (CDER): Guidance for Industry on Bioanalytical Method Validation","author":"US Food and Drug Administration","year":"2001"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521003873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521003873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:16:32Z","timestamp":1760001392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521003873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":29,"alternative-id":["S0731708521003873"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114276","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of UPLC\u2013MS\/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114276"}}